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Abstract
Background: Acute coronary syndrome (ACS) refers to a spectrum of life-threatening cardiac diseases usually due
to coronary artery plaque rupture, subsequent thrombin generation plaque activation and thrombus formation. To
date, no economic analyses have been published about the use of fondaparinux in NSTE-ACS patients in Canada.
The purpose of our study is to estimate the lifetime cost-effectiveness of fondaparinux compared to enoxaparin for
non-ST-elevation acute coronary syndrome (NSTE-ACS) patients in a Canadian hospital setting.
Methods: As an extension of a previous published economic analysis for US patients, an event-based decision analytic
model was constructed using clinical and resource use data from OASIS-5, a randomized trial of 20,078 patients from
41 countries. A public payer perspective in the hospital setting was adopted. Resource use data from the trial were
valued using Canadian costs. A cost regression model was developed to estimate the mean cost of managing the
clinical events over the 180 day period. Annual costs of long-term care for ACS patients were added after 180 days
until death. Long-term survival was incorporated using Canadian life tables with further adjustment for additional risks
associated with NSTE-ACS. Quality-of-life (utility) decrements from published sources were applied to clinical events.
Lifetime costs (2009 CAD$) and quality-adjusted life-years (QALYs), discounted annually at 5 %, were estimated for the
typical patient in OASIS-5 (i.e., at mean covariate values).
Results: The trial data showed that fondaparinux is protective against all clinical events observed in the trial. The model
showed that: over 180 days, fondaparinux dominates enoxaparin, producing similar estimates of QALYs gained and
saving $439; over a patient’s lifetime, fondaparinux yields an ICER of $4293/QALY. Based on PSA, the probabilities that
fondaparinux dominates enoxaparin (less costly and more effective) and that is cost-effective at a $50,000 threshold
were 42 % and 96 %, respectively.
Conclusions: In the Canadian hospital setting, fondaparinux is cost-effective when compared to enoxaparin for the
treatment of NSTE-ACS. This result holds both in the immediate post-event period and over the lifetimes of patients.
Keywords: Acute coronary syndromes, Health economics
Background
Acute coronary syndrome (ACS) refers to a spectrum of
life-threatening cardiac diseases usually due to coronary
artery plaque rupture, subsequent thrombin generation
plaque activation and thrombus formation.
Non-ST-elevation acute coronary syndrome (NSTE-ACS)
comprises 2 components: unstable angina (UA) and non-
ST-elevation myocardial infarction. Pharmacological rec-
ommendations and sequence of therapy will depend on the
individual management strategy and treatment guidelines,
but for both invasive and conservative strategies, a combin-
ation of antiplatelet and anticoagulation agents is recom-
mended. Most commonly, antiplatelet therapy will be
comprised of aspirin plus clopidogel and/or a glycoprotein
IIb/IIIa (GP) inhibitor, followed by an anticoagulant agent.
Options for anticoagulation therapy include fondaparinux
(Arixtra), unfractionated heparin (UFH) bivalirubin and
low-molecular heparins, such as enoxaparin.
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Fondaparinux is a well established synthetic anticoagu-
lant that inhibits thrombus formation by interrupting
the blood coagulation cascade through antithrombin
IIIA-mediated selective inhibition of factor Xa.
The Fifth Organization to Assess Strategies in
Acute Ischemic Syndromes Investigators (OASIS-5)
trial randomized 20,078 patients with NSTE-ACS to
fondaparinux or enoxaparin [1].
Patients were randomly assigned to a study group
within 24 h after the onset of symptoms and were
eligible if they met at least two of the three following
criteria: an age of at least 60 years, an elevated level of
troponin or creatine kinase MB isoenzyme, or electro-
cardiographic changes indicative of ischemia. Patients
with contraindications to low-molecular-weight heparin,
recent hemorrhagic stroke, indications for anticoagula-
tion other than an acute coronary syndrome, or a serum
creatinine level of at least 3 mg per deciliter (265 μmol
per liter) were excluded [2]. The study protocol was
approved by the respective ethics committees and regula-
tory bodies (ClinicalTrials.gov number, NCT00139815)
Additional file 1.
The Trial showed similar rates of ischemic events at
9 days but, by 180 days, fondaparinux reduced major
bleeding and improved mortality and morbidity.
To date, no economic analyses have been published
about the use of fondaparinux in NSTE-ACS patients
in Canada. As an extension of a previous published
analysis based on US patients [1], this article reports on
an evaluation of the costs and benefits of fondaparinux
and enoxaparin, in order to determine which one is
more cost-effective, both in short term (180 days) and
in the long term, using a life-time model in a Canadian
hospital setting.
Methods
This cost-effectiveness analysis was based on a published
and well-established methodology applied to estimate
the cost-effectiveness of fondaparinux versus enoxaparin
in the United States hospital setting [1]. Briefly, the
analysis consisted of 2 phases. First phase estimates the
differential cost of fondaparinux and enoxaparin over
180 days (mean OASIS-5 follow-up). The analysis relates
to a public-payer perspective in the Canadian hospital
setting. The second phase assessed long-term cost-
effectiveness in terms of costs and quality-adjusted life
years (QALYs). Costs and QALYs are discounted at 5 %
per annum.
An event-based decision analytical model was con-
structed using clinical and resource use data from OASIS-
5 and was previously published by Sculpher et al [1]. The
probabilities of death, non-fatal myocardial infarction
(MI), non-fatal stroke, and major and minor bleeds over a
period of 180 days, for both treatment strategies, were
estimated using a set of risk equations derived from
OASIS-5 data. Bleeding events are included in the cost
analysis but they are assumed not to affect long-term
prognosis.
In the short-term cost analysis, the differential cost of
each therapy was calculated by multiplying the estimated
cost of each event by the relevant event risk and summing
all the products. Decrements in health-related quality of
life (HRQoL) and long-term prognoses estimates were
used for the long-term cost-effectiveness analysis. A 5 %
annual discount rate was applied to all costs and QALYs.
Clinical events and resource use over a mean follow-up
of 173 days (range, 90–180 days) where used from the
OASIS-5 trial. This trial involved 20,078 patients with
NSTE-ACS which were randomized to either fondapari-
nux (2.5 mg daily) or enoxaparin (1 mg per kg twice daily)
for a mean of 5 days. This was a global study in which 41
countries participated including multiples hospitals
Canada. The primary end point of death, MI or refractory
ischemia at 9 days, was similar between treatments, but
major bleeding at 9 days was lower with fondaparinux [1].
The trial found significantly lower rates of death and
nonfatal events with fondaparinux at 180 days [1].
The differential cost of fondaparinux and enoxaparin
was based on the acquisition costs of the 2 therapies and
the product of 2 sets of estimates from the trial (i) risks
of key clinical events: death, nonfatal MI, nonfatal
stroke, a combination of MI and stroke and major and
minor bleeds (ii) the mean costs of these events. The
180-day probabilities of clinical events used OASIS-5
data and were based on parametric survival modeling
using a Weibull [3] distribution. The hazard of each
event is estimated as a function of treatment and
baseline covariates. The choice of covariates has
been based on the clinical judgment of and variables
used in the TIMI [4] and GRACE [4] risk scoring
systems.
Key resource use data in OASIS-5 included study
drugs, concomitant medications, and inpatient days. The
base-case analysis uses resource use data from the 1403
Canadian patients valued using Canadian costs (2009
$CAD), largely based on data obtained through the On-
tario Health Insurance Program (OHIP) [5–7]. These
costs include: medications, laboratory and diagnostic
procedures, therapeutic services, and primary and sec-
ondary diagnoses, total costs (fixed and variable) to the
hospital. Daily room costs are included for inpatient in-
terventions. In the case of procedures and interventions,
fees to medical professionals are estimated using the
Ontario Case Costing Initiative (OCCI), OHIP and the
published literature [8–10]. Drug costs are derived from
the Ontario Drug Benefit (ODB) formulary. Blood trans-
fusion costs are from ODB formulary and published
sources [11].
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In order to estimate the mean cost over 180 days of: (i)
patients without clinical events, and (ii) the additional cost
associated with each event, regression modeling was used.
An ordinary least squares model was used with a series of
dummy variables used to represent events. Concomitant
drug costs were based on the mean dosage in OASIS-5 and
the mean therapy duration in Canadian trial patients. In the
base case, these costs are based on the ODB formulary.
Patients remaining alive at 180 days will survive,
though with some decrements to their health, for a time
depending on sex, age and health state at 180 days.
Patients will also continue incurring costs for the treat-
ment of their heart disease. Long-term cost-effectiveness
assumes that the clinical differences between the alterna-
tive antithrombotics ceases at 180 days.
Since the OASIS-5 trial did not collect any data on
HRQoL, estimates are derived from other published
sources and applied to clinical events. Due to the unavail-
ability of Canadian-specific values, estimates were derived
from age-and sex-specific “population norms” for the
United States (US) based on EQ-5D instrument [12].
Long-term mortality rates are incorporated using
Canadian life tables. The additional mortality risk in
NSTE-ACS is quantified in terms of a relative risk com-
pared with the general population and distinguishes be-
tween patients with a nonfatal MI, a nonfatal stroke of any
severity, both types of nonfatal event or neither within
6 months of their ACS episode. This uses data from the
United Kingdom UK PRAIS study [13]. Beyond the initial
180-day period, the cost of long-term care for ACS
patients was assumed to be $10,783 per annum [14].
Mean (expected) cost-effectiveness of the probability
of each therapy being the least costly, and the more
cost-effective therapy assuming a cost-effectiveness
threshold of $50,000 per QALY gained is presented using
probabilistic sensitivity analysis (PSA) [15]. Short-term
costs and long-term cost-effectiveness are shown for the
“average” trial patient. Also, results are calculated for na-
tional patients at high and low risk of the composite
event of death and nonfatal MI and stroke with enoxa-
parin over 180 days, assuming the relative effect of
fondaparinux remains unchanged.
Lifetime costs and (QALYs) were estimated for the
typical patient in OASIS-5 (i.e., at mean covariate
values), as well as for a patient at the 2.5th and 97.5th
percentiles of composite risk of death, nonfatal MI or
nonfatal stroke. A cost analysis was performed at
180 days, and incremental cost-effectiveness ratios
(ICERs) were output over the entire lifetime. PSA was
carried out to assess parameter uncertainty.
Results
The risk equations showed consistent results with the
clinical analysis [2]. For each type of event over the
180-day follow-up period, fondaparinux was protective
compared with enoxaparin, although the effect was
Table 1 Summary of key resource use observed in the OASIS-5 trial patients randomized in Canada (n = 1.403) within the 180-day
follow-up period together with associated unitcosts (adapted from Table 2 in US analysis’)
Fondaparinux Enoxaparin
Item of resource use (n = 701) (n = 7 02) Unit cost (CAD 2009 S)
Sudy drugs (mean (SD) days) 4.10 (2.28) 3.65 (2.11) Enoxaparin: 15 per day a
Fondaparinux: 15 per day b
Days in hospital (mean (SD))
ICU 3.54 (5.07) 3.57 (3.83) 1433 per day
General ward 4.64 (10.13) 4.46 (9.61) 547 per day
Step down 2.98 (5.01) 2.85 (5.28) 547 per day
Selected concomitant medicines
Clopidcgrel (mean (SD) days) 105.25 (77.18) 106.07 (77.69) 2.58 per day
Ticlopidine (mean (SD) days) 0.08 (1.75) 1.04 (12.14) 0.55 per day
Glycoprotein llb/llla antagonists (n (%)) 201 (28.67) 212 (30.20) 1094
Selected procedures (n (%) with one or more) 47 (6.70) 39 (5.56) 543 per procedure
Blood transfusion 603 (86.02) 607 (86.47) 5401 per procedure
Coronary angiography 298 (42.51) 335 (47.72) 10,543 per procedure
Percutaneous coronary intervention 143 (20.40) 134 (19.09) 21,286 per procedure
Coronary artery bypass graft
SD Standard deviation, n Number, ICU Intensive care unit
aBased on 80 mg injection
bBased on 2.5 mg injection
Alfonso Ross Terres et al. BMC Cardiovascular Disorders  (2015) 15:180 Page 3 of 6
not statistically significant for nonfatal MI. (See Table 1 in
[1]). Table 1 shows key resource use over the 180-day fol-
low up in OASIS-5 in Canadian patients, together with es-
timated unit costs. Resource use was very similar between
enoxaparin and fondaparinux patients; the main difference
between fondaparinux and enoxaparin was in the rate of
percutaneous coronary intervention. Also, a higher
proportion of Canadian subjects needed blood trans-
fusion under fondaparinux, although this difference
was not statistically significant (relative risk (RR) of
having a blood transfusion: 1.21; 95 % confidence
interval: 0.80, 1.82). When considering all patients
randomized in the trial, the RR of having a blood
transfusion was 0.75 (0.65 to 0.86).
Table 2 presents the results of the short-term cost
analysis. The total expected costs of the two therapies
over 180 days shows fondaparinux was associated with
potential cost savings, although this finding was not
statistically significant.
The long-term cost-effectiveness analysis reported in
Table 3 showed that the ICER is well below conven-
tional thresholds for the 3 types of patients consid-
ered in the model (patients of average characteristics,
and patients at low and high risk of the composite
event of death, MI or stroke, respectively). The
uncertainty in these results is shown in terms of the
probabilities that fondaparinux is cost saving, and
cost-effective at a threshold of $50,000 per QALY
gained; these probabilities ranged from 34 to 48 %
and 83 to 97 %, respectively.
Discussion
After assessing the cost-effectiveness of the alternative
therapies reflecting Canadian practice based on resource
use, unit costs, age- and sex-specific population, mortality
risks and HRQoL data specific to the country, we found
that fondaparinux is cost-effective and, under most sce-
narios, a dominant strategy compared with enoxaparin. In
part, this reflects not only the lower acquisition cost of
fondaparinux but also the lower rates of clinical events
during the 6-month period after treatment.
There are limitations to modeling the cost-effectiveness of
products studied in multinational trials because studies are
powered on overall event rates, not event rates in individual
countries, yet local country resource use and cost data are
required for decision making. Therefore, to inform payers
in Canada, the model was based on Canadian resource use
from the trial, while using whole trial event rates.
At baseline in OASIS-5, Canadian patients were gener-
ally similar to those in the overall trial with some differ-
ences with the US population which were less likely to
have unstable angina (rather than MI), had undergone
more revascularization procedures, were more likely to
be diabetic, and were less likely to have ST-segment
depression. Differences in medical care between Canada
and the United States have been reported in the contem-
porary management of patients with non– ST-elevation
MI and UA. Several studies have reported findings in
which angiography, angioplasty, and bypass surgery are
more common in the United States than in Canada. The
differences could be explained in the availability on-site
Table 2 Six-month cost analysis comparison of the expected costs of enoxaparin and fondaparinux over six months (estimates relate to
a patient with “average” characteristics [4], adapted from Table 2 in US analysis’)
Cost of eventb (95 % Cl) Probability of event (95 % Cl) Cost per patientc (95 % Cl) (2009 CADS)
Event/resource use (2009 CAD $) Enoxaparin Fondaparinux Enoxaparin Fondaparinux
Death −691 (−4943, 3487) 0.046 (0.042, 0.050) 0.041 (0.038, 0.045) −28 (−225, 157) −2 5 (−203, 141)
Non-fata Ml 15,021 (10,997, 19,053) 0.049 (0.046, 0.055) 0.047 (0.043, 0.052) 752 (527, 978) 712 (505, 927)
Non-fatal stroke 18,755 (10,698, 26,864) 0.011 (0.009, 0.014) 0.007 (0.006, 0.009) 217 (113, 340) 141 (76, 226)
Non-fatal Ml & Stroke 3407 (−29,232, 35,980) 0.0006 (0.0005, 0.0007) 0.0003 (0.0003, 0.0005) 2 (−17, 20) 1 (−10, 13)
Major bleed 17,553 (13,827, 21,023) 0.052 (0.048, 0.057) 0.038 (0.034, 0.042) 921 (728, 1126) 665 (524, 823)
Minor bleed 3604 (171, 7182) 0.071 (0.066, 0.077) 0.036 (0.032, 0.040) 257 (10, 521) 129 (5, 254)
Enoxaparin Treatment 60 1 0 60 0
Fondaparinux Treatment 63 0 1 0 63
Other costsd 24,143 (22,785, 25,425) 1 1 24,143 (22,785, 25,425) 24,143 (22,785, 25,425)
Tota mean cost 26,302 (25,042, 27,473) 25,864 (24,689, 27,025)
Difference in mean costs $-439 (−2069, 1322)
Ml Myocardial infarction, Cl Confidence interval, CAD Canadian dollars
aCovariates at mean values are Age 67.1; proportion male 0 62; proportion with history’ of: heart failure 0 14. diabetes 0 25. hypertension 0 67. ST depression 0 51;
creatinine quartiles quartile 1 0 26. quartile 2 0 26. quartile 3 0 25. quartile 4 0 23
bResults of the cost regression relating to patients randomized in Canada (n = 1.403) (2009 CAD $)
cEstimated by multiplying the probability of event times cost of event, when performing the probabilistic sensitivity analysis
dBackground cost associated with patients who experienced ischemic heart disease
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facilities in different institutions across Canada which
could lead to longer waiting times which could have an
impact on long outcome of this population. This could be
reflection of longer stay in ICU and general ward [16].
As previously published in the original analysis
performed in the US population, fondaparinux resulted in
cost savings to the hospital [1]. When 180-day cost and
clinical results were extrapolated to long-term cost-
effectiveness, fondaparinux was dominant (less costly and
more effective in terms of QALYs under most scenarios.
The OASIS-5 trial reported that in the subgroup of pa-
tients undergoing percutaneous coronary intervention
(PCI), fondaparinux reduced major bleeding by one half
while maintaining similar efficacy to enoxaparin. This re-
sulted in superior net clinical benefit of fondaparinux rela-
tive to enoxaparin in PCI patients. In this analysis, both
enoxaparin and fondaparinux were associated with cath-
eter thrombosis in 1 % of patients. Consequently, it is rec-
ommended that, in patients treated with fondaparinux for
ACS, adjunctive UFH (50–60 IU/kg bolus) be used in
place of an IV fondaparinux bolus just before the PCI pro-
cedure. It has been shown in OASIS-5 that, even with the
use of supplemental UFH in PCI patients, the reduction in
bleeding with fondaparinux appears to be preserved [1].
Given this, and the modest cost of UFH relative to IV
fondaparinux, the use of adjunctive UFH can be
expected to have little effect on the cost-effectiveness
results presented here.
Conclusions
This analysis showed that differences in clinical events
over 180 days have long-term prognostic implications. In
the Canadian hospital setting, fondaparinux is cost-
effective when compared to enoxaparin for the treatment
of NSTE-ACS. This result holds both in the immediate
post-event period and over the lifetimes of patients.
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Table 3 Cost-effectiveness results over a lifetime time horizon (adapted from Table 2 in US analysis)
Enoxaparin Fondaparinux ICER
Patient with average characteristics
Expected cost $110,477 $110,661
$4293
Expected quality-adjusted life years 6.37 6.42
Probablity most cost-effective at a threshold of $50,000 per QALY 96 %
Probability of cost-saving 42 %
Patient at low risk of composite event over 180 days (2.5th percentile)
Expected cost $164,824 $164,836
$661
Expected quality-adjusted life years 11.01 11.03
Probability most cost-effective at a threshold of $50,000 per QALY 83 %
Probability of cost-saving 48 %
Patient at high risk of composite event over 180 days (97.5th percentile)
Expected cost $70,846 $71,299
$4666
Expected quality-adjusted life years 3.37 3.47
Probability most cost-effective at a threshold of $50,000 per QALY 100 %
Probability of cost-saving 34 %
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